Stockscreener 앱 받기
35.56
3.24%
-1.19
시간 외 거래:
35.53
-0.03
-0.08%
전일 마감가:
$36.75
열려 있는:
$37.8
하루 거래량:
13.59M
Relative Volume:
3.81
시가총액:
$4.15B
수익:
-
순이익/손실:
$-472.34M
주가수익비율:
-8.5771
EPS:
-4.1459
순현금흐름:
$-340.33M
1주 성능:
+22.66%
1개월 성능:
+4.07%
6개월 성능:
+7.11%
1년 성능:
+41.73%
1일 변동 폭
$35.10
$39.05
1주일 범위
$28.41
$43.10
52주 변동 폭
$24.88
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
35.56 | 4.15B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics Stock (VKTX) Opinions on Positive Obesity Drug Data Release - quiverquant.com
What Viking Therapeutics Stock Means For Shareholders After Obesity Drug Data And $500 Million Raise - simplywall.st
VKTX 10-Q FilingsViking Therapeutics, Inc SEC 10-Q - Stock Titan
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users? - Stocktwits
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (NASDAQ:VKTX) - Seeking Alpha
Is Viking Therapeutics (VKTX) Getting Too Rich After VK2735 Data? - finance.yahoo.com
Biotech Stocks To ResearchSeptember 25th - MarketBeat
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
VKTX Form 4 FilingsViking Therapeutics, Inc SEC Form 4 - Stock Titan
Is Viking Therapeutics, Inc. (VKTX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
Form 424B5 Viking Therapeutics Inc For: 25 September - Investing.com India
Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes - Legal Desire
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
Form 424B5 Viking Therapeutics Inc For: 25 September By Investing.com - Investing.com Canada
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits
Viking Therapeutics (VKTX) Stock Looks Fully Priced Despite Its Huge Five Year Run - simplywall.st
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - finance.yahoo.com
Viking Therapeutics Plunges After Upsized $500 Million Financing Prices at 16% Discount - finance.biggo.com
Viking Therapeutics Share Drop After Upsized Stock, Notes Offerings - Moomoo
One investor reportedly took a third of Viking’s share sale - au.finance.yahoo.com
Viking Therapeutics raises USD 500m to advance VK2735 obesity program - AllSci
Latham Advises on Viking Therapeutics Upsized Offering of Common Stock and Convertible Senior Notes - Latham & Watkins LLP
Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race - TipRanks
Here's Why Viking Therapeutics Shares Slumped Today - The Motley Fool
Top Biotech Stocks To Keep An Eye OnSeptember 24th - MarketBeat
Why Is Viking Therapeutics Stock Trading Down Thursday? - Benzinga
Viking Therapeutics drops 15% after $500M stock offering; Jaguar Health falls 25% without news. - Pluang
Viking Therapeutics Sinks 12% on “Upsized” $500 Million Raise - tikr.com
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25% - finance.yahoo.com
Biggest stock movers Thursday: P, VKTX, MGM, BE, and more - Seeking Alpha
Viking Therapeutics Prices Upsized Stock and Convertible Notes Offering at Discount - Intellectia AI
VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff - Yahoo Finance
What Did Viking Therapeutics (NASDAQ:VKTX) Maintenance Data Show for VK2735? - Kalkine Media
Viking Therapeutics Prices Upsized $500 Million Stock, Convertible Notes Offering - marketscreener.com
Viking Therapeutics (VKTX) Prices $490M Concurrent Offering Amid Unprofitable Growth Outlook - GuruFocus
Why is Viking Therapeutics stock tumbling today? By Investing.com - Investing.com Canada
Stitch Fix Posts Mixed Q4 Results, Joins Viking Therapeutics And Other Big Stocks Moving Lower In Thursda - Benzinga
Why is Viking Therapeutics stock tumbling today? - Investing.com
Viking Therapeutics raises $500M in upsized stock and notes offering - Dealroom
Viking Therapeutics prices $500M stock and debt offering - Investing.com
Viking Therapeutics prices $275M stock and conv... - Pluang
Viking Therapeutics prices $500M stock and debt offering By Investing.com - Investing.com Nigeria
Viking Therapeutics prices upsized $500M offering of common stock and convertible senior notes - TradingView
Viking Therapeutics Prices Upsized $500 Million Offering Of Common Stock And Convertible Senior Notes - TradingView
Viking Therapeutics, Inc. (VKTX) Prices Upsized $500M Stock and 2.00% Convertible Notes - TradingView
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks - Yahoo Finance
Positive VK2735 Clinical Data: Can Viking Therapeutics Displace Eli Lilly and Novo Nordisk? - NAI500
Is Viking Therapeutics (VKTX) Fully Valued On Its Positive VK2735 Trial Update? - simplywall.st
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):